Urologix hopes for much needed revenue boost with Medtronic's Prostiva
This article was originally published in Clinica
Urologix has gained exclusive worldwide distribution rights to Medtronic's Prostiva radiofrequency ablation device for the treatment of benign prostatic hyperplasia (BPH). The deal makes Urologix the leading provider of doctors' office-based treatments for obstructive urinary conditions caused by BPH – it already markets its own minimally-invasive treatment, Cooled ThermoTherapy (CTT).
Register for our free email digests: